Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Template:SubstanceBox/Pregabalin: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Isaak
No edit summary
>Graham
m wiki ref formatting
Line 70: Line 70:
     |OralROA_Collapsed=false
     |OralROA_Collapsed=false
     |OralROA_Caption='''WARNING:''' Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. <u>[[responsible drug use|See responsible use section]].</u><br> '''[[Disclaimer|DISCLAIMER]]:''' PW's [[dosage]] information is gathered from users and [[Network|resources]] for educational purposes only. It is not a recommendation.<br>'''This dosage and duration information has been sourced from [http://drugs.tripsit.me/pregabalin TripSit]'''
     |OralROA_Caption='''WARNING:''' Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. <u>[[responsible drug use|See responsible use section]].</u><br> '''[[Disclaimer|DISCLAIMER]]:''' PW's [[dosage]] information is gathered from users and [[Network|resources]] for educational purposes only. It is not a recommendation.<br>'''This dosage and duration information has been sourced from [http://drugs.tripsit.me/pregabalin TripSit]'''
     |OralROA_Bioavailability=~90%<ref>https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/0091270009352087</ref>
     |OralROA_Bioavailability=~90%<ref name="Bockbrader2010">{{cite journal | vauthors=((Bockbrader, H. N.)), ((Radulovic, L. L.)), ((Posvar, E. L.)), ((Strand, J. C.)), ((Alvey, C. W.)), ((Busch, J. A.)), ((Randinitis, E. J.)), ((Corrigan, B. W.)), ((Haig, G. M.)), ((Boyd, R. A.)), ((Wesche, D. L.)) | journal=The Journal of Clinical Pharmacology | title=Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers | volume=50 | issue=8 | pages=941–950 | date= August 2010 | url=http://doi.wiley.com/10.1177/0091270009352087 | issn=00912700 | doi=10.1177/0091270009352087}}</ref>
     |OralROA_Threshold=[[Oral threshold dose::50]] [[Oral dose units::mg]]
     |OralROA_Threshold=[[Oral threshold dose::50]] [[Oral dose units::mg]]
     |OralROA_Light=[[Oral min light dose::75]] - [[Oral max light dose::225]] mg
     |OralROA_Light=[[Oral min light dose::75]] - [[Oral max light dose::225]] mg

Revision as of 17:50, 27 July 2022

SubstanceBox/Pregabalin
Chemical Nomenclature
Common names Pregabalin, Lyrica, Nervalin
Substitutive name 3-Isobutyl GABA
Systematic name (S)-3-(Aminomethyl)-5-methylhexanoic acid
Class Membership
Psychoactive class Depressant
Chemical class Gabapentinoid
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Bioavailability ~90%[1]
Threshold 50 mg
Light 75 - 225 mg
Common 225 - 600 mg
Strong 600 - 900 mg
Heavy 900 mg +
Duration
Total 8 - 14 hours
Onset 40 - 120 minutes
Peak 4 - 6 hours
Offset 4 - 8 hours
After effects 4 - 10 hours




Rectal
Dosage
Bioavailability ~99%
Threshold < 40 mg
Light 40 - 200 mg
Common 200 - 450 mg
Strong 450 - 600 mg
Heavy 600 mg+
Duration
Total 5 - 8 hours
Onset 15 - 30 minutes
Come up 30 - 120 minutes
Peak 2 - 3 hours
Offset 3 - 5 hours
After effects 6 - 12 hours





DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

  1. Bockbrader, H. N., Radulovic, L. L., Posvar, E. L., Strand, J. C., Alvey, C. W., Busch, J. A., Randinitis, E. J., Corrigan, B. W., Haig, G. M., Boyd, R. A., Wesche, D. L. (August 2010). "Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers". The Journal of Clinical Pharmacology. 50 (8): 941–950. doi:10.1177/0091270009352087. ISSN 0091-2700.